Sigilon Therapeutics to Participate in the Jefferies London Healthcare Conference

Rhea-AI Summary

Sigilon Therapeutics (NASDAQ:SGTX) announced that its President and CEO, Rogerio Vivaldi, M.D., will participate in a prerecorded fireside chat at the Jefferies London Healthcare Conference on November 18, 2021, at 8:00 a.m. GMT. The chat will be available on-demand and can be accessed via the Company’s website under the Investors & Media section. Sigilon aims to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, utilizing engineered cell-based therapies to provide essential proteins and enzymes for conditions like hemophilia and diabetes.

CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will participate in a fireside chat during the upcoming Jefferies London Healthcare Conference. The prerecorded fireside chat will we available on-demand starting Thursday, November 18, 2021 at 8:00 a.m. GMT.

A webcast of the Jefferies fireside chat will be accessible under “Events and Presentations” in the Investors & Media page of the Company’s website at www.sigilon.com. A replay of the fireside chat will be available at the same location following the event.

About Sigilon Therapeutics
Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, lysosomal diseases and diabetes. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

FAQ

When will Rogerio Vivaldi participate in the Jefferies London Healthcare Conference for SGTX?

Rogerio Vivaldi will participate in the fireside chat on November 18, 2021, at 8:00 a.m. GMT.

How can I access the Sigilon Therapeutics fireside chat?

The fireside chat will be available on-demand on the Company’s website under the Investors & Media page.

What is the focus of Sigilon Therapeutics' Shielded Living Therapeutics™ platform?

The platform aims to develop functional cures for chronic diseases using engineered cell-based therapies.

What chronic diseases does Sigilon Therapeutics target with its therapies?

Sigilon focuses on chronic diseases such as hemophilia, lysosomal diseases, and diabetes.

Who founded Sigilon Therapeutics?

Sigilon was founded by Flagship Pioneering along with MIT's Daniel Anderson, Ph.D., and Robert Langer, Sc.D.